A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3

Inclusion Criteria: * Have a clinical diagnosis of chronic hepatitis C on the basis of detectable serum HCV RNA during the screening period and at least a 6-month history of exposure to risk factors for HCV. * Have never received treatment with an interferon alfa product or an interferon alfa combination product. * Have HCV genotype 2 or 3. * Have compensated liver disease with the following minimum criteria: white blood cell count (WBC) \>3,000/mm3, absolute neutrophil count (ANC) \> 1,800/mm3, platelets \>100,000/mm3, hemoglobin (Hb) \> 13 g/dL for males and \> 12 g/dL for females. Exclusion Criteria: * Evidence of decompensated liver disease. * Pregnant or lactating female. * History of any other medical disease or condition that would make the subject (in the opinion of the investigator) unsuitable for the study. * A current drug or alcohol addiction.